급성 호흡곤란 증후군 : 시장 인사이트, 역학 및 시장 예측(2036년)

Acute Respiratory Distress Syndrome (ARDS) Insights and Trends

• According to DelveInsight's analysis, the ARDS market size was found to be ~USD 1,700 million in the leading markets (the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan) in 2025.
• Among the 7MM, the US accounted for the largest market size of ARDS, i.e., USD ~1,300 million in 2025.
• ARDS is generally characterized by three stages such as exudative stage, the fibroproliferative (or proliferative) stage, resolution, and recovery stage.
• Early recognition of ARDS is important for the timely initiation of lung-protective ventilation strategies. Even after attempts to improve the definition of the disease, ARDS remains under-recognized by clinicians.
• There are currently no FDA-approved drugs that treat impaired lung function. Corticosteroids and nitric oxide are sometimes used to address the inflammatory component of ARDS, but these therapies have not consistently achieved good outcomes for most patients.
• The therapeutic landscape of ARDS is evolving with the emergence of new interventions and growing clinical evidence that continue to refine treatment strategies. Improvements in supportive care, particularly lung-protective ventilation and prone positioning, have enhanced patient outcomes; however, ARDS remains associated with significant morbidity and mortality, especially in cases complicated by extra-pulmonary organ dysfunction.
• Key Companies involved in the emerging treatment landscape of ARDS are Healios K.K, Direct Biologics, Athersys, Edesa Biotech, Herald Therapeutics, BioAegis Therapeutics, and others.

Acute Respiratory Distress Syndrome (ARDS) Market Size and Forecast in the 7MM

• 2025 ARDS Market Size: ~USD 1,700 million
• 2036 Projected ARDS Market Size: ~USD 3,200 million
• ARDS Growth Rate (2026-2036): ~3.8% CAGR

DelveInsight's 'Acute Respiratory Distress Syndrome (ARDS) - Market Insights, Epidemiology and Market Forecast - 2036' report delivers an in-depth understanding of the Acute Respiratory Distress Syndrome (ARDS), historical and forecasted epidemiology, as well as the Acute Respiratory Distress Syndrome (ARDS) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

The ARDS market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates Acute Respiratory Distress Syndrome (ARDS) patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment, and growth rate projections (Historical & Forecast 2022-2036) across global regions. The report highlights key unmet medical needs in ARDS and maps the competitive and clinical landscape to uncover high-value opportunities, providing a clear outlook on future market growth potential.

Key Factors Driving the Acute Respiratory Distress Syndrome (ARDS) Market

Rising incidence of ARDS and Respiratory Diseases

The increasing global burden of conditions such as pneumonia, sepsis, trauma, and viral infections (including COVID-19) is a major driver, leading to a growing number of ARDS cases.

High Unmet Medical Need and Lack of Targeted Therapies

ARDS still has limited effective, disease-specific treatments, with current management largely supportive (ventilation, ICU care), creating a strong unmet need that drives research, innovation, and market growth as companies attempt to develop targeted therapies. Increased Access to Healthcare Services.

Increase in Emerging Therapies

There is a significant rise in clinical trials and pipeline development, including biologics, stem cell therapies, and immunomodulators, which is accelerating innovation and attracting investment into the ARDS market.

Acute Respiratory Distress Syndrome (ARDS) Understanding and Treatment Algorithm

Acute Respiratory Distress Syndrome (ARDS) Overview and Diagnosis

ARDS is a severe, life-threatening form of acute respiratory failure characterized by rapid onset of widespread inflammation in the lungs, leading to increased permeability of the alveolar-capillary membrane, pulmonary edema, and impaired gas exchange. It commonly occurs secondary to conditions such as sepsis, pneumonia, trauma, or aspiration, and is defined clinically by acute hypoxemia and bilateral lung infiltrates not fully explained by cardiac failure, as outlined in the Berlin Definition of ARDS, with disease severity categorized based on the degree of oxygenation impairment.

Diagnosis of ARDS is primarily clinical and based on established criteria such as the Berlin Definition of ARDS, which includes acute onset within one week of a known insult, bilateral opacities on chest imaging (chest X-ray or CT scan), respiratory failure not explained by cardiac causes or fluid overload, and impaired oxygenation measured by the PaO2/FiO2 ratio; additional investigations such as arterial blood gas analysis, echocardiography (to exclude cardiogenic pulmonary edema), and laboratory tests are used to support diagnosis and identify the underlying cause.

Current Acute Respiratory Distress Syndrome (ARDS) Treatment Landscape

Management of ARDS is mainly supportive and focuses on optimizing oxygenation and treating the underlying cause. Key strategies include lung-protective mechanical ventilation with low tidal volumes, appropriate levels of positive end-expiratory pressure (PEEP), prone positioning in moderate to severe cases, and supportive intensive care measures such as fluid management and monitoring, while advanced options like extracorporeal membrane oxygenation (ECMO) may be considered in refractory cases to maintain adequate oxygenation. Several investigational therapies are currently under clinical trials, reflecting ongoing efforts to develop targeted pharmacological treatments for ARDS.

Acute Respiratory Distress Syndrome (ARDS) Unmet Needs

The section "unmet needs of ARDS" outlines the critical gaps between the current state of patient care, diagnosis, and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress.

1. Lack of disease-specific pharmacological therapies

2. Delayed and difficult early diagnosis

3. Dependence on intensive care resources

4. Heterogeneity of the disease, and others.....

Acute Respiratory Distress Syndrome (ARDS) Epidemiology

Key Findings from Acute Respiratory Distress Syndrome (ARDS) Epidemiological Analysis and Forecast

• According to DelveInsight's estimates, in 2025, the total number of incident cases of ARDS in the 7MM was ~980,000.
• Based on severity, moderate ARDS accounts for a higher proportion of cases compared to mild and severe ARDS.
• Pneumonia is the leading risk factor for ARDS, accounting for a significant proportion of cases, followed by sepsis.

Acute Respiratory Distress Syndrome (ARDS) Drug Analysis & Competitive Landscape

The ARDS drug chapter provides a detailed, market-focused review of the emerging pipeline across Phase III/II clinical trials. It covers the mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, and strategic partnerships, as well as upcoming key catalysts for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the ARDS treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the ARDS therapeutics market.

Acute Respiratory Distress Syndrome (ARDS) Pipeline Analysis

MultiStem (HLCM051): Healios K.K

MultiStem (HLCM051) is an allogeneic, off-the-shelf somatic stem cell therapy developed by Healios K.K. (Japan) in collaboration with Athersys (US). This regenerative cell therapy is being developed for ARDS, acting through anti-inflammatory signaling, immune modulation, and tissue repair. The therapy has received US FDA Fast Track Designation (FTD) and Regenerative Medicine Advanced Therapy (RMAT) designations, and ODD in Japan. The RMAT designation was received in April 2022. Although it has shown promising safety and biological activity in studies, it remains in the clinical development stage and has not yet received full regulatory approval as a marketed therapy.

ExoFlo (DB-2Q): Direct Biologics

ExoFlo, developed by Direct Biologics, is an extracellular signal product derived from human bone marrow mesenchymal stem or stromal cells that delivers bioactive signals to reduce inflammation, support intercellular communication, and promote tissue repair. The therapy showed favorable safety and meaningful efficacy in a Phase II study in hospitalized adults with COVID-19-related moderate-to-severe ARDS, supported further by positive outcomes from an expanded access program.

Acute Respiratory Distress Syndrome (ARDS) Key Players, Market Leaders and Emerging Companies

• Healios K.K
• Direct Biologics
• Athersys
• Edesa Biotech
• Herald Therapeutics
• BioAegis Therapeutics, and others

Acute Respiratory Distress Syndrome (ARDS) Drug Updates

• In January 2026, Healios submitted a clinical trial plan notification to the Pharmaceuticals and Medical Devices Agency (PMDA) for a clinical trial to be conducted in Japan as part of the Global Phase III trial (REVIVE-ARDS) for HLCM051 for the treatment of ARDS.
• In February 2026, Edesa Biotech, in its SEC filing (8K), reported that it is evaluating subgroup data for additional efficacy signals among subjects with certain comorbidities following positive results from a Phase III study of its monoclonal antibody, paridiprubart, in patients with ARDS.
• In April 2026, Edesa Biotech, in its corporate presentation, announced that the US allocated USD 117 million to evaluate three novel therapeutics for general ARDS, including Edesa's paridiprubart.
• In September 2024, HEALIOS K.K announced that they held an End-of-Phase II consultation with the FDA regarding the launch of a pivotal, global Phase III study to demonstrate and confirm the efficacy and safety of MultiStem for ARDS caused by pneumonia, primarily in the United States.
• In April 2023, Direct Biologics announced favorable safety and efficacy data from its ExoFlo expanded access program in hospitalized adult COVID-19 patients with moderate-to-severe ARDS.
• In July 2023, Direct Biologics announced favorable safety data and significant efficacy results from its Phase II clinical trial of ExoFlo in hospitalized adult COVID-19 patients with moderate-to-severe ARDS.

Acute Respiratory Distress Syndrome (ARDS) Market Outlook

The Acute Respiratory Distress Syndrome (ARDS) market remains largely centered on supportive care.

Beyond supportive care, the ARDS pipeline is evolving toward immunomodulatory and regenerative approaches, aiming to address the underlying pathophysiology of inflammation, endothelial injury, and immune dysregulation. Investigational therapies such as MultiStem (HLCM051), ExoFlo (DB-2Q), and EB05 (paridiprubart) are being developed to modulate immune responses, reduce inflammation, and promote tissue repair, with several candidates progressing through Phase II and Phase III clinical trials, reflecting a shift from purely supportive management to targeted biological therapies.

• Among the 7MM, the US accounted for the largest market size of ARDS, i.e., USD ~1,300 million in 2025.
• The entry of late-stage candidates such as HLCM051 and ExoFlo (DB-2Q) is expected to intensify competition in the ARDS treatment landscape during the latter half of the forecast period.

Drug Class/Insights into Leading Emerging and Marketed Therapies in Acute Respiratory Distress Syndrome (ARDS) (2022-2036 Forecast)

The ARDS market comprises immune modulators, immune regulators, and targeted therapies, each targeting different aspects of ARDS.

• Immune modulator: Pipeline candidate HLCM051 is an allogeneic cell-based regenerative therapy that acts as an immune modulator by reducing systemic inflammation, restoring immune balance, and promoting endogenous tissue repair in injured lung tissue.
• Targeted therapy: EB05 is a monoclonal antibody-based targeted immunotherapy designed to inhibit key inflammatory signaling pathways, thereby reducing immune-mediated lung injury and progression of ARDS.

mRNA Vaccine defines the core innovation landscape, driving pipeline growth.

Acute Respiratory Distress Syndrome (ARDS) Drug Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during the forecast period (2026-2036). The analysis covers the ARDS drug's uptake, performance at peak, factors affecting performance during prime years of growth, patient uptake by therapy, and anticipated sales generated by each drug.

The uptake of therapies in ARDS is expected to vary based on clinical positioning, mechanism of action, and stage of development. Pipeline candidates such as HLCM051, ExoFlo (DB-2Q), and EB05 (paridiprubart) are expected to follow a cautious to moderate uptake trajectory, driven by encouraging early- to mid-stage clinical signals in critically ill patients with hyperinflammatory lung injury. Phase I/II and early Phase III studies have shown signals of improved oxygenation, reduced inflammatory markers, and acceptable safety profiles, particularly in subsets of patients with severe or COVID-19-associated ARDS. However, broader clinical adoption is expected to remain dependent on the successful completion of ongoing Phase III trials.

Detailed insights of emerging therapies' drug uptake is included in the report

Market Access and Reimbursement of Approved Therapies in Acute Respiratory Distress Syndrome (ARDS)

Reimbursement may be referred to as the negotiation of a price between a manufacturer and a payer that allows the manufacturer access to the market. It is provided to reduce the high costs and make the essential drugs affordable. Health technology assessment (HTA) plays an important role in reimbursement decision-making and recommending the use of a drug. These recommendations vary widely throughout the seven major markets, even for the same drug. In the US healthcare system, both Public and Private health insurance coverage are included. Also, Medicare and Medicaid are the largest government-funded programs in the US. The major healthcare programs, including Medicare, Medicaid, Health Insurance Program (CHIP), and the state and federal health insurance marketplaces, are overseen by the Centres for Medicare & Medicaid Services (CMS). Other than these, Pharmacy Benefit Managers (PBMs) and third-party organisations that provide services and educational programs to aid patients are also present.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of currently used therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

NOTE: Further Details are provided in the final report....

Acute Respiratory Distress Syndrome (ARDS) Therapies Price Scenario & Trends

Pricing and analogue assessment of ARDS therapies highlights evolving price dynamics structures. This section summarizes the cost of approved treatments, the closest and most appropriate analogue selection for emerging therapies, and the understanding of how pricing influences market access, adherence, and long-term uptake.

Industry Experts and Physician Views for Acute Respiratory Distress Syndrome (ARDS)

To keep up with ARDS market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on the ARDS emerging therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns in ARDS, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight's analysts connected with 15+ KOLs to gather insights at the country level. Centers such as the Yale School of Medicine, Upstate Medical University, and Osaka University Graduate School of Medicine, etc. were contacted. Their opinion helps understand and validate current and emerging ARDS therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for market access, therapy adoption, and pipeline prioritization in ARDS.

Qualitative Analysis: SWOT and Conjoint Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and conjoint analysis.

In the SWOT analysis of ARDS, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The team of analysts analyzes promising emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial's primary and secondary outcome measures are evaluated, whereas the therapies' safety is evaluated, wherein the acceptability, tolerability, and adverse events are majorly observed. In addition, the scoring is also based on the route of administration, order of entry, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Scope of the Report:

• The report covers a segment of key events, an executive summary, a descriptive overview of ARDS, explaining their causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the ARDS market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM ARDS market.

Report Insights

• Acute Respiratory Distress Syndrome (ARDS) Patient Population Forecast
• Acute Respiratory Distress Syndrome (ARDS) Therapeutics Market Size
• Acute Respiratory Distress Syndrome (ARDS) Pipeline Analysis
• Acute Respiratory Distress Syndrome (ARDS) Market Size and Trends
• Acute Respiratory Distress Syndrome (ARDS) Market Opportunity (Current and forecasted)

Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• Artificial Intelligence (AI)-Enabled Market Research Report
• 11-Year Forecast
• Acute Respiratory Distress Syndrome (ARDS) Market Outlook (North America, Europe, Asia-Pacific)
• Patient Burden Trends (By Geography)
• Acute Respiratory Distress Syndrome (ARDS) Treatment Addressable Market (TAM)
• Acute Respiratory Distress Syndrome (ARDS) Competitive Landscape
• Acute Respiratory Distress Syndrome (ARDS) Major Companies Insights
• Acute Respiratory Distress Syndrome (ARDS) Price Trends and Analogue Assessment
• Acute Respiratory Distress Syndrome (ARDS) Therapies Drug Adoption/Uptake
• Acute Respiratory Distress Syndrome (ARDS) Therapies Peak Patient Share Analysis

Report Assessment

• Acute Respiratory Distress Syndrome (ARDS) Current Treatment Practices
• Acute Respiratory Distress Syndrome (ARDS) Unmet Needs
• Acute Respiratory Distress Syndrome (ARDS) Clinical Development Analysis
• Acute Respiratory Distress Syndrome (ARDS) Emerging Drugs Product Profiles
• Acute Respiratory Distress Syndrome (ARDS) Market attractiveness
• Acute Respiratory Distress Syndrome (ARDS) Qualitative Analysis (SWOT and conjoint analysis)

FAQs:

Market Insights

• What was the ARDS market size, the market size by therapies, market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of ARDS?
• What are the disease risks, burdens, and unmet needs of ARDS? What will be the growth opportunities across the 7MM concerning the patient population with ARDS?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of ARDS? What are the current guidelines for treating ARDS in the US, Europe, and Japan?

Reasons to Buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the ARDS market.
• Bottom up forecasting builds from the affected population to product forecasts, delivering a robust, data driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• To understand KOLs' perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
• This Artificial Intelligence (AI) enabled report summarize and simplify complex datasets with in the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Key Events

• 4.1. Upcoming Key Catalysts
• 4.2. Key Conferences And Meetings
• 4.3. Key Transactions And Collaborations
• 4.4. News Flow

5. Epidemiology and Market Methodology of Acute Respiratory Distress Syndrome (ARDS)

6. Acute Respiratory Distress Syndrome (ARDS) Market Overview at a Glance

• 6.1. Emerging Landscape Analysis (By Molecule Type, Phase, and Route of Administration [ROA])
• 6.2. Market Share of Acute Respiratory Distress Syndrome (ARDS) By Therapies (%) in the 7MM in 2025
• 6.3. Market Share of Acute Respiratory Distress Syndrome (ARDS) By Therapies (%) in the 7MM in 2036

7. Disease Background And Overview of Acute Respiratory Distress Syndrome (ARDS)

• 7.1. Introduction
• 7.2. Causes
• 7.3. Signs And Symptoms
• 7.4. Diagnosis
  • 7.4.1. Differential Diagnosis
  • 7.4.2. Diagnostic Algorithm
• 7.5. Treatment and Management

8. Epidemiology and Patient Population of Acute Respiratory Distress Syndrome (ARDS)

• 8.1. Key Findings
• 8.2. Assumption and Rationale
• 8.3. Total Incident Cases of Acute Respiratory Distress Syndrome (ARDS) in the 7MM
• 8.4. The United States
  • 8.4.1. Total Incident Cases of Acute Respiratory Distress Syndrome (ARDS) in United States
  • 8.4.2. Severity-specific Incident Cases of Acute Respiratory Distress Syndrome (ARDS) in United States
  • 8.4.3. Incident Cases of Acute Respiratory Distress Syndrome (ARDS) by Risk Factors in United States
• 8.5. EU4 and the UK
  • 8.5.1. Total Incident Cases of Acute Respiratory Distress Syndrome (ARDS) in EU4 and the UK
  • 8.5.2. Severity-specific Incident Cases of Acute Respiratory Distress Syndrome (ARDS) in EU4 and the UK
  • 8.5.3. Incident Cases of Acute Respiratory Distress Syndrome (ARDS) by Risk Factors in EU4 and the UK
• 8.6. Japan
  • 8.6.1. Total Incident Cases of Acute Respiratory Distress Syndrome (ARDS) in Japan
  • 8.6.2. Severity-specific Incident Cases of Acute Respiratory Distress Syndrome (ARDS) in Japan
  • 8.6.3. Incident Cases of Acute Respiratory Distress Syndrome (ARDS) by Risk Factors in Japan

9. Patient Journey of Acute Respiratory Distress Syndrome (ARDS)

• 9.1. Patient Description

10. Emerging Therapies

• 10.1. Emerging Competitive Landscape of Acute Respiratory Distress Syndrome (ARDS)
• 10.2. MultiStem (HLCM051): Healios K.K
  • 10.2.1. Product Description
  • 10.2.2. Other Developmental Activities
  • 10.2.3. Clinical Development
    • 10.2.3.1. Clinical Trial Information
  • 10.2.4. Safety and Efficacy
  • 10.2.5. Analyst Views
• 10.3. ExoFlo (DB-2Q): Direct Biologics
  • 10.3.1. Product Description
  • 10.3.2. Other Developmental Activities
  • 10.3.3. Clinical Development
    • 10.3.3.1. Clinical Trial Information
  • 10.3.4. Safety and Efficacy
  • 10.3.5. Analyst Views

11. Acute Respiratory Distress Syndrome (ARDS): Seven Major Market Analysis

• 11.1. Key Findings
• 11.2. Market Outlook of Acute Respiratory Distress Syndrome (ARDS)
• 11.3. Conjoint Analysis of Acute Respiratory Distress Syndrome (ARDS)
• 11.4. Key Market Forecast Assumptions
  • 11.4.1. Cost Assumptions
  • 11.4.2. Pricing Trends
  • 11.4.3. Analogue Assessment
  • 11.4.4. Launch Year and Therapy Uptakes
• 11.5. Total Market Size of Acute Respiratory Distress Syndrome (ARDS) in the 7MM
• 11.6. The United States
  • 11.6.1. Total Market Size of Acute Respiratory Distress Syndrome (ARDS) in the United States
  • 11.6.2. Market Size of Acute Respiratory Distress Syndrome (ARDS) by Therapies in the United States
• 11.7. EU4 and the UK
  • 11.7.1. Total Market Size of Acute Respiratory Distress Syndrome (ARDS) in EU4 and the UK
  • 11.7.2. Market Size of Acute Respiratory Distress Syndrome (ARDS) by Therapies in EU4 and the UK
• 11.8. Japan
  • 11.8.1. Total Market Size of Acute Respiratory Distress Syndrome (ARDS) in Japan
  • 11.8.2. Market Size of Acute Respiratory Distress Syndrome (ARDS) by Therapies in Japan

12. Unmet Needs of Acute Respiratory Distress Syndrome (ARDS)

13. SWOT Analysis of Acute Respiratory Distress Syndrome (ARDS)

14. KOL Views of Acute Respiratory Distress Syndrome (ARDS)

• 15.1. Expert/KOL Interview Highlights

16. Market Access and Reimbursement of Acute Respiratory Distress Syndrome (ARDS)

• 16.1. The US
• 16.2. In EU4 and the UK
  • 16.2.1. Germany
  • 16.2.2. France
  • 16.2.3. Italy
  • 16.2.4. Spain
  • 16.2.5. United Kingdom
• 16.3. Japan
• 16.4. Summary and Comparison of Market Access and Pricing Policy Developments in 2025

17. Appendix

• 17.1. Bibliography
• 17.2. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight